BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Actis GC, Pellicano R, Ribaldone DG. A Concise History of Thiopurines for Inflammatory Bowel Disease: From Anecdotal Reporting to Treat-to-Target Algorithms. Rev Recent Clin Trials 2019;14:4-9. [PMID: 30198438 DOI: 10.2174/1574887113666180910120959] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Ribaldone DG, Caviglia GP, Pellicano R, Vernero M, Italia A, Morino M, Saracco GM, Astegiano M. Adalimumab versus azathioprine to halt the progression of bowel damage in Crohn’s disease: application of Lémann Index. Scandinavian Journal of Gastroenterology 2019;54:1339-45. [DOI: 10.1080/00365521.2019.1686057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Allen PB, Bonovas S, Danese S, Peyrin-Biroulet L. Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective. Expert Opin Biol Ther 2020;20:151-61. [PMID: 31815548 DOI: 10.1080/14712598.2020.1702020] [Reference Citation Analysis]
3 Ribaldone DG, Resegotti A, Pellicano R, Astegiano M, Saracco GM, Morino M. The role of topical therapy for perianal fistulizing Crohn's disease: are we forgetting something? Minerva Gastroenterol Dietol 2019;65:130-5. [PMID: 30759975 DOI: 10.23736/S1121-421X.19.02565-0] [Reference Citation Analysis]
4 Hernandez Santana YE, Irwin N, Walsh PT. IL-36: a therapeutic target for ulcerative colitis? Expert Opin Ther Targets 2022;:1-6. [PMID: 35634891 DOI: 10.1080/14728222.2022.2084381] [Reference Citation Analysis]
5 Armandi A, Bonetto S, Pellicano R, Caviglia GP, Astegiano M, Saracco GM, Ribaldone DG. Dupilumab to target interleukin 4 for inflammatory bowel disease? Hypothesis based on a translational message. Minerva Biotecnol 2019;31. [DOI: 10.23736/s1120-4826.19.02556-4] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
6 Wlazło M, Kierkuś J. Dual Biologic Therapy for the Treatment of Pediatric Inflammatory Bowel Disease: A Review of the Literature. JCM 2022;11:2004. [DOI: 10.3390/jcm11072004] [Reference Citation Analysis]
7 Actis GC, Pellicano R, Fagoonee S, Ribaldone DG. History of Inflammatory Bowel Diseases. J Clin Med. 2019;8:1970. [PMID: 31739460 DOI: 10.3390/jcm8111970] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 10.3] [Reference Citation Analysis]
8 Ribaldone DG, Pellicano R, Actis GC. The gut and the inflammatory bowel diseases inside-out: extra-intestinal manifestations. Minerva Gastroenterol Dietol 2019;65:309-18. [PMID: 30994321 DOI: 10.23736/S1121-421X.19.02577-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 4.7] [Reference Citation Analysis]
9 Sarno A, Varello S, Debani P, Bonenti G, Robotti D. Intestinal ultrasonography in adults with Crohn's disease: a 2020 update. Minerva Gastroenterol Dietol 2019;65:335-45. [PMID: 31760739 DOI: 10.23736/S1121-421X.19.02638-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
10 Ribaldone DG, Adriani A, Caviglia GP, Nicolò A, Agnesod D, Simiele M, Riganò D, Pellicano R, Canaparo R, Perri GD, D'Avolio A, Luzza F, Saracco GM, Astegiano M. Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients. Medicina (Kaunas) 2019;55:E441. [PMID: 31387318 DOI: 10.3390/medicina55080441] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
11 Castellano F, Alessio G, Palmisano C. Ocular manifestations of inflammatory bowel diseases: an update for gastroenterologists. Minerva Gastroenterol (Torino) 2021;67:91-100. [PMID: 32677418 DOI: 10.23736/S2724-5985.20.02727-0] [Reference Citation Analysis]
12 Ribaldone DG, Pellicano R, Vernero M, Caviglia GP, Saracco GM, Morino M, Astegiano M. Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis. Scandinavian Journal of Gastroenterology 2019;54:407-13. [DOI: 10.1080/00365521.2019.1597159] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]